An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction


Creative Commons License

ÇİÇİN İ., Oukkal M., Mahfouf H., Mezlini A., Larbaoui B., Ben Ahmed S., ...More

EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.1, pp.63-73, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 1
  • Publication Date: 2022
  • Doi Number: 10.4274/ejbh.galenos.2021.2021-9-9
  • Journal Name: EUROPEAN JOURNAL OF BREAST HEALTH
  • Journal Indexes: Emerging Sources Citation Index (ESCI), TR DİZİN (ULAKBİM)
  • Page Numbers: pp.63-73
  • Keywords: subcutaneous, trastuzumab, breast cancer, HER2, patient satisfaction, ADJUVANT CHEMOTHERAPY, FINAL ANALYSIS, SAFETY, TOLERABILITY, EXPERIENCE
  • Istanbul University Affiliated: Yes

Abstract

Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).